Zimmer Biomet Holdings, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Zimmer Biomet Holdings, Inc. stock analysis ZBH overview
Bullish +65

Zimmer Biomet to pay up to $140M for Iovera nerve therapy

🤝 Zimmer Biomet agrees to acquire Pacira's Iovera nerve therapy technology for a total value up to $140 million.

💰 The deal structure includes a $70 million upfront payment plus potential milestone payments through late 2031.

📅 The transaction is projected to close in the third quarter of 2026.

🧬 Zimmer Biomet will assume full rights for development, manufacturing, and commercialization of Iovera.

🤝 Pacira retains a portion of compensation contingent on successful registrational study completion and regulatory approval.

❄️ Iovera utilizes cryoneurolysis to provide drug-free pain relief by temporarily interrupting nerve signals.

🦵 The device is FDA-cleared for treating osteoarthritis knee pain with efficacy lasting up to 90 days.

💊 Clinical data indicates a 45% reduction in opioid consumption over 12 weeks post-surgery among patients.

📈 Pacira CEO Frank D. Lee cites the deal as advancing their transition into an innovative biopharmaceutical company.

🌍 The partnership aims to leverage Zimmer Biomet's global scale to expand patient access worldwide.

Bullish Signals
  • Zimmer Biomet secures a strategic asset in pain management with a total deal value reaching up to $140 million, including significant milestone potential.
  • The acquisition of Iovera allows Zimmer Biomet to integrate FDA-cleared cryoneurolysis technology into its existing orthopedic portfolio.
  • Pacira BioSciences achieves a strategic pivot toward biopharmaceuticals with a major partner in Zimmer Biomet, validating their technology platform.
  • Iovera demonstrates strong clinical efficacy with a 45% reduction in opioid consumption and significant improvements in knee function scores.
Full Analysis
Zimmer Biomet has agreed to acquire Iovera nerve therapy technology from Pacira BioSciences for a total value of up to $140 million. The deal includes an upfront payment of $70 million, with the remainder consisting of potential revenue-based milestone payments scheduled through December 31, 2031. The transaction is expected to close in the third quarter of 2026. Upon completion, Zimmer Biomet will obtain all rights to develop, manufacture, and commercialize Iovera, while Pacira retains a share of compensation tied to the successful completion of a registrational study and subsequent regulatory approval for their joint spasticity program. Iovera is an FDA-cleared, drug-free medical device that utilizes cryoneurolysis to relieve pain by temporarily interrupting nerve signals. Originally acquired by Pacira in 2019 for $220 million, the technology is indicated for relieving osteoarthritis knee pain for up to 90 days and has shown significant efficacy in reducing opioid consumption post-surgery. This acquisition aligns with Zimmer Biomet's strategy to expand its orthopedic portfolio and Pacira's transition into an innovative biopharmaceutical company. The deal leverages Zimmer's global scale and commercialization expertise to potentially unlock the full market potential of Iovera for pain management globally.